Russell R. Moores

A comparison of nitrogen mustard, vincristine, procarbazine, and prednisone (mopp) vs. nitrogen mustard in advanced hodgkin's disease

A randomized study of patients with advanced Hodgkins disease was designed to determine whether the improved therapeutic effectiveness of combination chemotherapy was due to the use of a combination of drugs or might be achieved with a single agent if given as intensively and for as long a period. A combination of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) was compared with nitrogen mustard (HN2) alone. Treatment with both regimens was given to tolerance on cyclic basis and was continued for six cycles of treatment. Sixty‐one evaluable patients were treated with MOPP and 47 with HN2. The complete remission rate of 47.5% with MOPP was significantly better than the 12.8% with HN2 (p < .05). Complete remission lasted a median of 15 months after MOPP and 12 months after HN2. The survival of patients initially treated with MOPP was significantly better than that of those initially treated with HN2.

Potentiation of Purified Erythropoietin with Serum Proteins

1 Non‐neutralizing antiserum, normal rabbit, human and mouse sera potentiate the erythropoietic activity of anaemic human urinary Fraction II + III. This substantiates the concepts introduced by Kuratowska, Lewartowski and Lipinski. 2 Orosomucoid (alpha‐1 acidic‐glycoprotein) similarly potentiates the erythropoietic activity of anaemic human urinary Fraction II + III. 3 The erythropoietic activity of Standard B was not enhanced by the addition of serum proteins. 4 The erythropoietic activity of human urinary concentrates was enhanced by the addition of normal serum proteins and suggestive enhancement of anaemic human serum and plasma was noted.

Multiple myeloma associated with a 9S IgG paraprotein and carcinoma of the prostate

A case of multiple myeloma associated with a 9S IgG complex. kappa‐type light chains, and adenocarcinoma of the prostate is described. The relative amount of 9S globulin was independent of total protein concentration; it was the predominant M‐component in both highly diluted serum and also in whole serum. At low pH, it was dissociated to the 7S monomer. The presence of moderately high concentrations of the 9S species in the patients serum did not cause symptoms of the hyperviscosity syndrome. A review of the literature suggests that the association of myeloma with nonreticular neoplasms may occur more often than previously supposed.

Potentiation of purified erythropoietin with serum proteins. II. Serial dose response relationships.

Summary Erythropoietin (urinary fraction II + III) was diluted with either saline or normal serum and injected into assay animals as a single dose or as 2 or 4 fractional doses either intraperitoneally or subcutaneously. Erythropoietic activity increased as the dose was fractionated; however, the erythropoietin plus serum showed greater activity than erythropoietin plus saline in all dosage schedules. This suggests that normal serum actually enhances the activity of erythropoietin rather than merely acting as an adjuvant causing delayed absorption of the material. Grateful acknowledgement is made to Miss Bettie Williams and Mrs. Carol Cope for fine technical assistance, to Dr. Charles B. Bragassa, Mrs. Rebecca Bedingfield and Mr. Bob Ellis of the Computer Center, Medical College of Georgia, for statistical analyses and to Mrs. Margaret Hiers and Mrs. Shirl Melton for secretarial assistance.

The Selective Inactivation of an ESF-Generating Factor (EGF) in the Presence of Erythropoietin (ESF)

Summary An ESF-generating factor (EGF), erythropoietin (ESF) and a mixture of both were incubated with dithiothreitol (DTT, a protective reagent for sulfhydryl groups). Ten μM DTT completely prevented the production of 0.26 ± 0.01 IU of ESF by EGF but did not inactivate ESF. DTT was used to indicate the relative amounts of EGF and ESF activity in a mixture of both.

The Selective Membrane Filtration of an ESF-generating Factor (EGF) in the Presence of Erythropoietin (ESF)

Summary A mixture of an erythropoiesis stimulating factor (ESF) and an ESF-generating factor (EGF), isolated from the urine of a patient with paroxysmal nocturnal hemoglobinuria (PNH), was separated by selective membrane filtration. The optimum pH for activity of the EGF fraction from the urine of the PNH patient was about 7.4, the same as that previously found for the EGF from the urine of a patient with an anemia secondary to multiple myeloma (MM). The urine from the PNH patient contained an ESF that appeared larger than EGF, whereas the urine from the MM patient did not; the urine from both patients, however, contained an ESF that appeared smaller than EGF as previously noted.